Lantern Pharma Inc.

NasdaqCM:LTRN Rapporto sulle azioni

Cap. di mercato: US$33.2m

Lantern Pharma Gestione

Gestione criteri di controllo 4/4

Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.

Informazioni chiave

Panna Sharma

Amministratore delegato

US$684.4k

Compenso totale

Percentuale dello stipendio del CEO76.8%
Mandato del CEO6.3yrs
Proprietà del CEOn/a
Durata media del management4.9yrs
Durata media del Consiglio di amministrazione6.3yrs

Aggiornamenti recenti sulla gestione

Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Dec 28
Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Recent updates

Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?

Nov 05
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Jun 12
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Feb 28
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Nov 06
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

Jul 20
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Apr 04
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Dec 19
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Sep 02
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer

Jul 14

Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

May 20
Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

Feb 02
Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation

We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Oct 13
We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely

Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer

Aug 24

Lantern Pharma: Drug Recycling With AI

Jun 08

We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

May 05
We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate

Lantern Pharma reports Q1 results

May 03

Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Feb 19
Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like

Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma

Jan 04

Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Dec 28
Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?

Lantern: Early Stage 'Smart Drug' Discovery Company

Nov 25

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Panna Sharma rispetto agli utili di Lantern Pharma?
DataCompenso totaleStipendioGuadagni aziendali
Sep 30 2024n/an/a

-US$19m

Jun 30 2024n/an/a

-US$18m

Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$684kUS$525k

-US$16m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$14m

Mar 31 2023n/an/a

-US$14m

Dec 31 2022US$1mUS$475k

-US$14m

Sep 30 2022n/an/a

-US$14m

Jun 30 2022n/an/a

-US$16m

Mar 31 2022n/an/a

-US$14m

Dec 31 2021US$622kUS$432k

-US$12m

Sep 30 2021n/an/a

-US$12m

Jun 30 2021n/an/a

-US$9m

Mar 31 2021n/an/a

-US$8m

Dec 31 2020US$2mUS$384k

-US$6m

Sep 30 2020n/an/a

-US$4m

Jun 30 2020n/an/a

-US$3m

Mar 31 2020n/an/a

-US$2m

Dec 31 2019US$332kUS$267k

-US$2m

Dec 31 2018US$353kUS$105k

-US$2m

Compensazione vs Mercato: La retribuzione totale di Panna ($USD 684.39K ) è circa la media per le aziende di dimensioni simili nel mercato US ($USD 652.28K ).

Compensazione vs guadagni: La retribuzione di Panna è stata coerente con le performance aziendali dell'ultimo anno.

AMMINISTRATORE DELEGATO

Panna Sharma (53 yo)

6.3yrs

Mandato

US$684,385

Compensazione

Mr. Panna Sharma has been the Chief Executive Officer and President of Lantern Pharma Inc. since July 26, 2018 and has been its Director since August 29, 2018. As Chief Executive Officer, Mr. Sharma overse...

Gruppo dirigente

NomePosizioneMandatoCompensazioneProprietà
Panna Sharma
President6.3yrsUS$684.39kNessun dato
David Margrave
CFO & Secretary6.4yrsUS$442.68kNessun dato
Kishor Bhatia
Chief Scientific Officer & Scientific Consultant4.9yrsUS$283.24kNessun dato
Nicole Leber
Investor Relations Associateno dataNessun datoNessun dato
Peter Nara
Co-Founder & Advisorno dataUS$794.00Nessun dato
Ernest Kitt
Head of Clinical Operations1.7yrsNessun datoNessun dato
Marc Chamberlain
Chief Medical Officer of Starlight Therapeuticsless than a yearNessun datoNessun dato

4.9yrs

Durata media

63yo

Età media

Gestione esperta: Il team dirigenziale di LTRN è considerato esperto (durata media dell'incarico 4.9 anni).

Membri del Consiglio di amministrazione

NomePosizioneMandatoCompensazioneProprietà
Panna Sharma
President6.3yrsUS$684.39kNessun dato
Vijay Chandru
Independent Director5.1yrsUS$46.00kNessun dato
Maria Maccecchini
Independent Director2.4yrsUS$51.00kNessun dato
Donald Keyser
Independent Chairman6.8yrsUS$56.00k0.39%
$ 129.1k
David Silberstein
Independent Director6.4yrsUS$46.00kNessun dato

6.3yrs

Durata media

71yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di LTRN sono considerati esperti (durata media dell'incarico 6.3 anni).